SCHEMBL3090840

SCHEMBL3090840

O=C(O)C(Cc1ccccc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LARS1 Q9P2J5 1/20 0.58
F2 P00734 2/20 0.56
LMNA P02545 1/20 0.54
SLC1A3 P43003 1/20 0.52
SLC1A2 P43004 1/20 0.52
SLC1A1 P43005 1/20 0.52
CYP19A1 P11511 1/20 0.51
ALDH1A1 P00352 1/20 0.50
KAT6A Q92794 2/20 0.49
PPARG P37231 1/20 0.48
PPARA Q07869 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
RAPGEF3 O95398 1/20 0.47
POLB P06746 1/20 0.47
NPY5R Q15761 1/20 0.47
NLRP3 Q96P20 1/20 0.46
MMP2 P08253 3/20 0.46
MMP9 P14780 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3090045 0.93 LARS1 (0.57) LARS1F2LMNASLC1A3SLC1A2
SCHEMBL3103948 0.92 KAT6A (0.55) LARS1F2LMNASLC1A3SLC1A2
SCHEMBL3090769 0.91 LARS1 (0.53) LARS1F2LMNASLC1A3SLC1A2
SCHEMBL3097005 0.91 LARS1 (0.53) LARS1F2LMNASLC1A3SLC1A2
SCHEMBL3091186 0.91 LARS1 (0.53) LARS1F2LMNASLC1A3SLC1A2
SCHEMBL3096994 0.90 LARS1 (0.52) LARS1F2LMNASLC1A3SLC1A2
SCHEMBL3090763 0.90 LARS1 (0.52) LARS1F2LMNASLC1A3SLC1A2
SCHEMBL3092119 0.89 KAT6A (0.51) LARS1F2LMNASLC1A3SLC1A2
SCHEMBL3088714 0.89 KDM4E (0.58) LARS1F2ALDH1A1KAT6APPARG
SCHEMBL3089900 0.88 LARS1 (0.50) LARS1F2LMNASLC1A3SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LARS1 1976/4885F2 4128/4885LMNA 3803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.